# A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer

> **NCT02225093** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 12 (actual)

## Conditions studied

- Pharmacokinetics of Dextromethorphan
- Pharmacokinetics of Caffeine
- Prostate Cancer

## Interventions

- **DRUG:** Caffeine
- **DRUG:** Dextromethorphan
- **DRUG:** Enzalutamide
- **DRUG:** Enzalutamide Placebo to Match (PTM)

## Key facts

- **NCT ID:** NCT02225093
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-02
- **Primary completion:** 2014-02-03
- **Final completion:** 2014-02-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02225093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02225093, "A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02225093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*